As of 2026-03-06, the EV/EBITDA ratio of Sigilon Therapeutics, Inc. (SGTX) is -0.93. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SGTX's latest enterprise value is 32.33 mil USD. SGTX's TTM EBITDA according to its financial statements is -34.77 mil USD. Dividing these 2 quantities gives us the above SGTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.1x - 15.6x | 15.4x |
| Forward P/E multiples | 17.3x - 21.1x | 19.2x |
| Fair Price | (229.57) - (206.07) | (229.23) |
| Upside | -1121.7% - -1017.1% | -1120.1% |
| Date | EV/EBITDA |